Sun Pharma $12B Historic US Outbound M&A
Key Questions
What is Sun Pharma's major US acquisition deal?
Sun Pharma is acquiring Organon in the US for $12 billion, the largest outbound M&A by an Indian pharmaceutical company. This deal doubles its specialty health portfolio.
Why is this Sun Pharma deal considered historic?
It marks the biggest Indian pharma outbound acquisition to date. The $12B transaction highlights growing cross-border ambitions in the sector.
What financial and regulatory aspects surround Sun Pharma's Organon acquisition?
Sun Pharma reported strong Q4 earnings amid integration and debt from $12B financing, with term sheets and agreements under tracking. The deal faces tests on cross-border and antitrust regulations.
Sun Pharma acquires Organon (US) for $12B, largest Indian pharma outbound, doubling specialty health; TT&A on $12B financing, Q4 earnings strong amid integration/debt, tests cross-border/antitrust.
Sources (2)
Updated May 7, 2026